Cannabis Investments

Cannabis Science Provides Product Line Guidance With Summary of Products In Development And Available On The Market Today

April 24, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is providing an update and summary of our goals and product line advancements. Some products are currently available to patients with legal state medical marijuana access, and others are up and coming over-the-counter products that will be available to the public nationally and internationally.

Cannabis Science is currently working towards making critical cannabis-based medications more widely available. To this aim, we have initiated, with our FDA advisory group, the pre-IND process. Unlike most conventional treatments, cannabis medicines and formulations have an outstanding safety profile, going back thousands of years. They allow patients in states with medical cannabis laws to safely make informed decisions to legally self-administer various cannabis-based preparations.

The medication will specifically target skin cancers including basal and squamous cell carcinomas. Judging by the results of the squamous cell carcinoma treatment studies Cannabis Science has already undertaken (see cannabisscience.com), we believe we have a breakthrough treatment for squamous cell carcinomas that are resistant to convention chemo- and radiation therapies.

Currently, Cannabis Science has cannabis-based, high quality oil available in Pueblo and Denver Colorado through licensing agreements. The oil, is packaged in oral dispensing syringes for patient self-administration. We have received excellent feedback regarding these products, specifically from patients suffering cancer and chronic pain.

In addition to the license agreements with dispensary and FDA products, Cannabis Science is very excited about the over the counter skin and nutraceutical product lines that are currently in development. Sunscreen, skin and face moisturizer, lip balm, and anti-aging serum will be available over the counter in drugstores and other retail outlets. Dr. Moe Afaneh, Cannabis Science’s Chief Operations Officer, is heading the development of this product line, and with his decade of successful experience in pharmaceutical product marketing, branding, and compounding prescriptions, he is aiding Cannabis Science tremendously in moving these projects forward. Cannabis Science is also in final discussions to finalize the brand name for the initial product line.

The Company’s intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States and the world where legally available.

Dr. Bob Melamede stated “Cannabis Science is excited that we are developing profit centers that will come online and create revenue in 2012. In addition to the revenues that we believe will be created with the Cannabis Extract Based prescription medicines and over-the-counter formulations, Cannabis Science has the ability to generate revenues now through the partnership with Vincent Mehdizadeh of Medical Dispensing Solutions, and consulting revenues Kaneabis acquisition. It is our goal to self- fund the FDA IND application and approval process as much as possible, that funding is generated from these additional profit centers.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com

View full post on News Releases

Cannabis Science’s COO Dr. Afaneh Provides Guidance On The Newest Over The Counter Product Line To Be Released

March 1, 2012

DENVER–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis and hemp products, has identified the four Cannabis Science brand products as the newest over the counter line to be released.

Cannabis science is among the leading experts specializing in developing all natural organic bio healing hemp health, beauty & cosmetics products. Our philosophy is to bring the best products possible to the entire world, to help improve & promote a healthier natural way of life with untold benefits. Our belief in achieving success is by providing superior products that are born from scientific data and research. From our years of dedication and hard work we have come to a new understanding in the keys to our product development.

Among our leading products is our sunscreen & protectant. Why our product is far superior to others is we have invested time into understanding what occurs in the body and skin, and targeting the cascade of events that occurs when people get sunburn. We have meticulously targeted key components that lead to the sunburn and have created our elite formulation that upon application, you instantly feel the skin begin to cool, the pain begins to dissipate and the healing process has begun. We have created our own cascade of healing properties using the finest natural ingredients to mimic or body’s natural pathway when responding to a skin burn. By combining certain ingredients that are coupled together produce a synergistic effect and also the sequence in which our ingredients are added into our formulation is key to our elite product.

Among our other popular topical skin care products, is our skin irritation for helping provide relief to various skin conditions such as eczema and other recurring skin irritations. We have looked at various populations and age groups that suffer from acute & chronic skin irritations. These symptoms varied from raised dry patches of skin, red blotches, hardened patches most appearing areas of the arms and legs, and a consistently itching from the histamine release of the body, as well as areas of the body that tended to constantly rub against clothing or other surfaces; including other parts of the body. Our specialized formulation was designed based on understanding what the patients’ expectations are from and over the counter skin care product. By understanding patients needs, we created our all natural unique formulation to help meet patients needs and improve their quality of life on daily basis. Our skin irritation cream targets the area thru multi-system approach. It is designed to help stop the itching and pain, first and foremost, and then begins to lock moisture in and around the area, and then our natural blend of ingredients begins to help the body heal the skin and reduce the irritation.

Among our novelty products is an anti-aging skin serum. Specifically formulated to meet the needs of woman and help rejuvenate and soften the skin. Using our science coupled with understanding what women expect from an anti-aging product, we used a multi-system approach to create the ultimate anti-aging serum. Using only natural ingredients, including hemp oil extract and many other natural oils and ingredients. Our serum helps to soften the skin, by providing key essential nutrients that are used in the right proportions and produced in a specialized combination; it leaves the skin looking radiant, energized, softer, healthier, and full of life.

Among our leading cosmetic products, is our all-natural lip balm that contains hemp oil extract and our unique blend of ingredients? Our lip balm is unique in that it has natural ingredients that help protect against bacteria and fungus, it also has SPF to protect against the harmful effects of the sun, infused with antioxidants and many other natural extracts it helps to soften the lips and lock the moisture in. Once again we used science and asked the right questions of our patients to understand their needs and what the expect from a lip balm. We achieved with our natural ingredients and extracts are able to meet those expectations; giving women the feeling of soft, juicy, radiant, and healthier looking lips.

The Cannabis Science executive team is finalizing negotiations for the manufacture and national distribution of this new product line. Commercialization is underway, including securing manufacturing partners with the resources to support the national distribution and retail outlets. Negotiations will continue when the first prototypes are received by Cannabis Science to be reviewed by various nationwide product distributors eagerly hoping to release this new line of products.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
or
Robert Kane
Investor Relations Management
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Issues Corporate & Operations Guidance to Shareholders in Regards to Dividend, Market Potential, and Anecdotal Reports

February 2, 2012

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.ob – News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to report an overall corporate and operations guidance outlook as very positive for 2012.

Cannabis Sciences’ analysis of the worldwide market potential for its formulations for medical cannabis treatments of critical ailments include three main markets for distribution: FDA approved prescriptions, OTC Non-psychoactive nutraceuticals, and licensed dispensaries in legal Medical Marijuana states (currently 16).

Due to this successful self medicating patient use of our cannabis extract based formulations in Colorado and other international anecdotal cases reports from patients with Cancer, Cannabis Science is pursing its FDA initiatives immediately with its initial indication targets including basal cell and squamous cell carcinomas.

The Company is currently tracking several self medicating cancer patients, there have been anecdotal reports, apparently successful, of self-medicated cannabis treatment for several cancer patients, including one whose physician said it was “the worst case of squamous cell carcinoma cancer he had ever seen,” while another physician refused to continue tending. Images and biopsy reports available on the www.cannabisscience.com website.

Cannabis Science is currently assessing market makers for the required 15c211 filing for the new class of shares to commence trading. The 15c211 filing is one of the many steps required to issue and commence trading with the new class of shares to be issued from the dividend including a new CUSIP number and new trading symbol.

On November 3, 2011, Cannabis Science, Inc.(the “Company”), filed an amendment to its Articles of Incorporation to create an additional class of common stock pursuant to the Company’s Definitive Information Statement on Schedule 14C which was filed with the Securities and Exchange Commission on August 18, 2011 (information incorporated by reference herein).

Upon completion, the Company will have three classes of shares: Class A Common Stock (new class), Class B Common Stock (current class) and Series A Preferred Stock. Only two of the classes will trade; Class A Common and Class B common will each trade with its own separate trading symbol. The Company will issue the dividend to its shareholders of record as of December 31, 2010, so they receive 1 share of the new Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the current common stock that they owned as of the shareholder record date. The Company will continue to report progress as the process continues to move forward until competition.

The company has announced that they have a variety of cannabis-based formulations that target critical ailments worldwide as outlined in the company website. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. The Company has a patient oriented, holistic approach to healing with whole plant cannabis extract formulations. We are dedicated to working with Federal, State, and Local regulatory agencies, as well as similar agencies in other countries such as Health Canada, and other international regulatory bodies.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contacts
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Issues First Market and Revenue Guidance in Regards to the Top 10 Cancer Formulations the Company Intends Focus on over Next Ten Years

December 14, 2011

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that we have a variety of cannabis-based formulations that target critical ailments worldwide. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. As outlined on the company website www.cannabisscience.com our initial target of self-administered cancer formulations proves to be the fastest to market application as prompted by recent successful cannabis-based treatments outlined in earlier press releases issued by the Company.

Marketresearch.com says cancer is the second-leading cause of death in the United States, and the world market for cancer therapy is growing at a brisk double-digit pace of over 10% per year, with total treatments revenues surpassing $40 billion this year in the USA alone.

Current market research and analysis shows Cannabis Science in a position to capitalize on the current annual cancer revenues at the low end of scale at approximately 1% market share giving the company a projected $400 million total revenues per year less associated costs.

The Top Ten Cancers and their respective markets Cannabis Science intends to focus on in regards to their formulations are Basal Cell Carcinoma and Squamous Cell Carcinoma (Skin Cancers), Ductal Carcinoma (Breast Cancer), Colon Cancer, Glioma (Brain Tumor), Lung Cancer, Multiple Myeloma (Bone Marrow), Ovarian Cancer, Pheochromocytoma (Adrenal Gland), and Prostate Cancer.

Cannabis Science estimates that there are over 7 million patients who suffer from these cancers in the USA alone and who could potentially benefit from the Cannabis Science Based Extract formulations as they initially become available in states with appropriate medical marijuana laws.

Robert Kane, Investor Relations Manager stated, “Our primary goals here at Cannabis Science in regards to increasing shareholder value started with more efficient communication and increased guidance in regards to the revenue and earnings potential of their business model. With the establishment of the Facebook and Twitter accounts, and the incredible support they have given me, it has allowed Cannabis Science to answer and respond to shareholder inquiries much more efficiently than in the past. Now, with this release of this market and revenue guidance, I applaud Dr. Melamede and his team for accomplishing these goals, and doing it so in such an efficient manner. Cannabis Science vigilantly continues to work on their projections and forecasts of their products for potential conditions that Cannabis Science will focus on in the future these projections and forecasts include different global geographical market and different medical conditions going forward over the next ten years. I look forward to sharing that guidance as it approved.”

Dr. Robert Melamede, President of Cannabis Science stated, “This information contained in this guidance demonstrates that we have a viable business model. We will generate revenues from our strategic alliance with MEDBOX, as well as from our Cannabis Extract Based Formulations. These revenue streams, as well as additional ones that we are currently working on, will allow us to fund our FDA efforts on a national level while we test and develop products on the medical marijuana state level.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek, “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Robert Kane, 561-234-6929
Investor Relations
rkane@kaneabis.com
or
Dr. Robert Melamede, President
www.cannabisscience.com
info@cannabisscience.com

View full post on News Releases

Cannabis Science Brand Releases Worldwide Growth Guidance For Its Formulations Targeting Critical Ailments

December 21, 2011

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB – News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to release its analysis of the worldwide market potential for medical cannabis treatments of critical ailments. There are three main markets for distribution, FDA approved prescriptions, OTC Non-psychoactive Neutroceuticals, and licensed dispensaries in legal Medical Marijuana states (currently 16). The Company has a patient oriented, holistic approach to healing with whole plant cannabis extract formulations. We are dedicated to working with Federal, State, and Local regulatory agencies, as well as similar agencies in other countries such as Health Canada, and other international regulatory bodies.

We know and appreciate the unique ability of pytocannabinoids to holisitcally tap into the human endocannabinoid system and help restore biochemical balance. Currently, we are focused on producing top of the line products for MMJ patients at a state level. Cannabis Science has begun with two extract-based formulations currently released to licensed Colorado patients (Cannabis Science CT-1 and Cannabis Science MT-1, both available through Marisol Therapeutics in Pueblo West, CO, and Cannabis Therapeutics in Colorado Springs, CO). These dispensaries carry our unique formulations that are currently, exclusively available for self-administration by Colorado State licensed medical marijuana patients, especially for those with cancer and other severely debilitating illnesses. We are in serious negotiations to expand this type of operation to other medical marijuana states.

INITIAL MARKET OPPORTUNITIES FOR CANNABIS SCIENCE WHOLE PLANT PHARMACEUTICALS

Dr. Robert J. Melamede Ph.D., states, “The actual worldwide market for treating critical ailments with Cannabis Science formulation amounts to trillions of dollars. This number is so high because cannabis-based medicines have been prohibited and discouraged for over 70 years. The explosion of modern scientific inquiry into the uniquely all pervasive endocannabinoid system provides a foundation of peer-reviewed science that can overcome resistance. Congress has an approval rating of less that 10% while over 80% of Americans favor the availability of medical marijuana. Cannabis Science believes that our products will spearhead the solution to the growing healthcare crisis in the US and abroad by their ability to correct endocannabinoid imbalances with holisitc, plant-based medicines.”

FORMULATION REVENUES WILL FALL INTO TWO MAIN CATEGORIES:

1. Licensing by product and by territory/country/continent:
This is common pharmaceutical industry practice. (For example: Otsuka $18 million payment to license for Sativex®) Licensing may be a source of revenue in the first year, but none is projected until the second year.

2. Royalties Payments:
The licensing agreements will lead to royalties on the sales of over-the-counter (dispensary) products in the second year, and prescription products in third and subsequent years. Cannabis Science will also benefit from the cross licensing of products developed by licensees domestically and internationally. Thus, if the licensees develop a product in partnership with Cannabis Science, that product would be marketed in the US by Cannabis Science and its affiliates, while meeting all applicable regulatory guidance.

WHOLE PLANT CANNABIS SCIENCE PHARMACEUTICAL PRODUCTS

1. Psychoactive Medicines (FDA Approved Drugs)

2. Non-psychoactive Neutroceuticals

3. Botanical Medicine

4. Dietary Supplements, i.e. Hemp-Based Foods

5. Skin care products i.e. Topical Lotions, Salves, Balms, Creams

Our efforts are propelled by our enthusiasm that grows as we acquire the anecdotal results that guide us. The first patient who self-administered Cannabis Science formulations had basal cell carcinoma on the face. Three lesions were ultimately successfully treated on this individual. This patient happily did not require any surgery after simple topical treatment with cannabis extracts. Similary, another patient with squamous cell carcinoma is having dramatic results after self-administering our extracts. We expect to have these results documented in the near future.

TARGETED CANNABIS SCIENCE BRAND DELIVERY METHODS

1. Extracts

2. Pills

3. Creams

4. Liquids

5. Strips

6. Lozenges

WHERE DO YOU FIT INTO THE PICTURE?

“Become the change you want to see.” –Gandhi

i. Analytical Labs

ii. Horticulture Division

iii. Pharmaceutical grade medical cannabis grown under stringent quality controls.

iv. Cutting-edge facilities for creating oral and topical medications for various ailments.

v. Initial clinical trials for FDA approval will target cancer.

vi. State of the art manufacturing facilities for cannabis based extracts and pharmaceutical grade drugs.

vii. Distribution In-state dispensaries today, national pharmacies tomorrow.

“Invest in Change! The Patient’s Voice for Alternative Medicines the Science for the People that will Change the World! Cannabis Science.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.